[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-m7w6sh0omF2i47xZ-eB6A1SGod5sdFIh9K7_3a3kaQ":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":12,"question":19,"related":20,"source":24,"type":25},[],"2025-11-18 15:31:35",226906037,[8,9,10,11],"10年内","终身","8年内","5年内",{"count":13,"courseId":14,"courseImg":15,"courseName":16,"workId":17,"workName":18},45,"68ae0dd0e6bada3b06ffb8270067090f","https:\u002F\u002Ftihai-oss-cloud.itihey.com\u002Fimg\u002F9f13f1ddf26a90881de0027d9cc37b55.png","药事管理与法规","work_46566661","项目二药品与药品管理","从事生产、销售假药的企业,其直接负责的主管人员和其他直接负责人不得从事药品生产、经营活动的年限是",[21,26,35,44,54,63,72,82,91,100],{"answer":22,"createTime":5,"id":6,"options":23,"question":19,"source":24,"type":25},[],[8,9,10,11],"v1",0,{"answer":27,"createTime":5,"id":28,"options":29,"question":34,"source":24,"type":25},[],226906038,[30,31,32,33],"在启动召回计划3日内,应将调查评估报告和召回计划提交给国家药品监督管理部门备案","药品生产企业应每日向国家药品监督管理部门报告召回进展情况","一级召回只适用于使用后可能引起暂时的或可逆的健康危害的药品","在作出召回决定后24小时内,应通知有关药品经营企业、使用单位停止销售和使用需召回的药品","根据药品安全隐患的严重程度,药品召回分为三级.下面有关一级召回的说法正确的是",{"answer":36,"createTime":5,"id":37,"options":38,"question":43,"source":24,"type":25},[],226906039,[39,40,41,42],"变质的","药品所含成分与国家药品标准规定成分不符的","药品成分含量不符合国家药品标准","以非药品冒充药品或者以其他药品冒充此种药品","下列情形中为劣药的是",{"answer":45,"createTime":5,"id":46,"options":47,"question":53,"source":24,"type":25},[],226906040,[48,49,50,51,52],"临床必需、安全有效、价格合理、使用方便、市场能够保证供应","安全、有效、合理、经济","保证品种和质量、引入竞争机制、合理控制成本、方便购药和便于管理","防治必需、安全有效、价格合理、使用方便、中西药并重、基本保障、临床首选和基层能够配备","防治必需、安全有效、价格合理、使用方便、中西药并重、基本保障、临床首选","国家基本药物遴选原则是",{"answer":55,"createTime":5,"id":56,"options":57,"question":62,"source":24,"type":25},[],226906041,[58,59,60,61],"稳定性","有效性","无毒性","安全性","药品质量特性不包括",{"answer":64,"createTime":5,"id":65,"options":66,"question":71,"source":24,"type":25},[],226906042,[67,68,69,70],"红色专业标识可作为经营甲类非处方药企业的指南性标识","红色专有标识用于甲类非处方药","绿色专有标识用于乙类非处方药","非处方药专有标识应与药品标签、使用说明书、内包装、外包装一体化印刷","关于非处方药专有标识的说法,错误的是",{"answer":73,"createTime":5,"id":74,"options":75,"question":81,"source":24,"type":25},[],226906043,[76,77,78,79,80],"临床药理学","临床治疗首选程度","药品通用名称","药物经济学","安全性评估结果","根据《国家基本药物目录管理办法暂行》,国家基本药物目录中生物制品分类的主要依据是",{"answer":83,"createTime":5,"id":84,"options":85,"question":90,"source":24,"type":25},[],226906044,[86,87,88,89],"处方应当经执业药师审核,调配处方应当经过核对,对处方所列药品不得擅自更改或代用","调配处方后,药学服务人员应当对照处方,核对药品名称,规格,进行数量标签以及个人消费者姓名,性别,年龄等,信息正确无误的方可销售","对有配伍禁忌的或超剂量的处方应当拒绝调配,必要时经执业药师更正或确认签重新签字后,方可调配销售","药品零售企业销售处方药应当按照国家处方药与非处方药分类管理有关规定,凭处方销售,处方药处方保留不少于5年","关于药品零售企业销售处方药的要求的说法,错误的是",{"answer":92,"createTime":5,"id":93,"options":94,"question":99,"source":24,"type":25},[],226906045,[95,96,97,98],"乙药品生产企业未按照要求提交其生产药品的定期安全性更新报告","甲药品生产企业未建立和保存其生产药品的药品不良反应监测报告档案","丙药品经营企业未配合药品生产企业按照要求开展的针对其生产的、发生群体不良事件的药品的调查、评价和处理","丁医疗机构不配合药品生产企业按照要求开展的针对其生产的、发生严重药品不良反应的药品的相关调查工作","根据《药品不良反应报告和监测管理办法》,关于药品生产、经营企业及医疗机构违法应承担的法律责任,除给予警告、责令限期改正并处罚款等外,其相应药品将不予再注册的情形是",{"answer":101,"createTime":5,"id":102,"options":103,"question":108,"source":24,"type":109},[],226906046,[104,105,106,107],"非处方药专用标识图案分为绿色和红色","甲类非处方药专用标识为红色","经营非处方药的企业指南性专用标识为红色","乙类非处方药专用标识为绿色","根据《非处方药专用标识管理规定暂行》,关于非处方药标识管理规定的说明正确的是",1]